The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

This was the stock's second consecutive day of losses.

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...

Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy according to billionaires. Some experts view medical ...

Bristol Myers Squibb's drug to treat a type of heart disease did not significantly improve functional capacity and symptoms in patients, failing to meet the main goals of a late-stage study ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report). The company’s ...

The stock's fall snapped a two-day winning streak.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...